Abstract:
본 발명은 피부 미용 및 성형용 조성물에 관한 것으로, 보다 상세하게는 백화사설초 추출물을 유효성분으로 함유하여 사람 중간엽줄기세포를 지방세포로 분화하는 것을 촉진시킴으로써 지방세포를 생성하여 피부의 볼륨과 탄력을 부여하는 미용 또는 성형 조성물에 관한 것이다. 백화사설초 * 중간엽 줄기세포 분화 * 지방세포생성
Abstract:
본 발명은 피부 기능 향상 물질을 스크리닝(screening)하는 방법으로서, (a) 후보 물질을 피부 세포에 처리하는 단계; (b) MAP17(Membrane-Associated Protein 17kD) 유전자의 상대적 발현량 변화를 검출하는 단계; 및 (c) 상기 유전자의 발현량 변화를 유도하는 후보 물질을 피부 기능 향상 물질로 선택하는 단계를 포함한다. 즉, 본 발명은 MAP17(Membrane-Associated Protein 17kD) 유전자를 표지인자로 하여 MAP17 유전자의 발현량 변화를 통해 피부 기능 향상 물질을 검색하는 신규한 스크리닝 방법으로서, 이를 통해 피부 장벽 기능 향상, 피부 보습 유지, 피부 노화 방지 또는 피부 트러블 완화에 유용한 피부 기능 향상 물질을 효율적으로 스크리닝할 수 있다. MAP17(Membrane-Associated Protein 17kD), 스크리닝
Abstract:
PURPOSE: A medicinal composition for preventing or treating diabetes and plastic surgery is provided to promote adipocyte differentiation and to enhance volume and elasticity of skin. CONSTITUTION: A medicinal composition for promoting differentiation of adipocytes contains (-)catechin, (-)epicatechin gallate, or (-)gallocatechin as an active ingredient. Adipocyte is human bone marrow mesenchymal stem cell. The (-)catechin, (-)epicatechin gallate, or (-)gallocatechin is isolated from green tea. A medicinal composition for treating and preventing type II diabetes and diabetes complication contains the (-)catechin, (-)epicatechin gallate, or (-)gallocatechin.
Abstract:
PURPOSE: A method and composition for promoting skin regeneration using icariside II is provided to promote proliferation of transient amplifying cells of epidermis base and promote skin regeneration. CONSTITUTION: An icariside II of chemical formula 1 promotes proliferation of skin cells in skin cells. The skin cell is transient amplifying cells(TA cells). A composition for promoting skin regeneration contains the icariside II as an active ingredient. The content of the active ingredient is 0.001-10 weight% based on total weight. The composition regenerates epidermis by promoting proliferation of the TA cells. The composition increases the number of TA cells which express CD71 protein (Cluster of Differentiation 71 Protein) and α6 integrin. The composition increases the expression of CD200(Cluster of Differentiation 200).
Abstract:
PURPOSE: A pharmaceutical composition for suppressing adipocyte differentiation and reducing lipid droplet is provided to prevent or treat obesity or lipoma. CONSTITUTION: A pharmaceutical composition of adipocyte differentiation contains arachidonyl dopamine. The pharmaceutical composition prevents adipose tissue enlargement-related disease. The adipose tissue enlargement-related disease is obesity or lipoma. The differentiation of adipocyte is from mesenchymal stem cell to adipocyte. The mesenchymal stem cell is human bone marrow mesenchymal stem cell. A formulation of oral administration is used in the form of pill, powder, suspension, emulsion, syrup, and granule.
Abstract:
Provided is 2,4,5-trisubstituted-1,3-thiazole derivatives having excellent inhibiting activity about SPC(sphingosylphosphorylcholine) receptor to treat inflammatory diseases caused by activity of the SPC acceptor. A therapeutic agent for treating inflammatory diseases caused by activity of SPC acceptor comprises a 2,4,5-trisubstituted-1,3-thiazole derivative represented by the formula 1 and pharmaceutically allowable salts thereof. A method for preparing the 2,4,5-trisubstituted-1,3-thiazole derivative consists of the following steps of: reacting methyl cyanocarbonimidodithionate represented by the formula 2 to 2-haloacetophenone in order to synthesize 4-amino-1,3-thiazol represented by the formula 3; and polymerizing chloridation carboxylic acid to 4-amino group of the 4-amino-1,3-thiazol to synthesize 4-N-acyl-1,3-thiazole represented by the formula 4.